IDEXX Outlines Diagnostic Growth Strategy, Including Expansion into Canine Cancer Testing
At the Morgan Stanley Global Healthcare Conference, IDEXX Laboratories reaffirmed its long-term growth targets of more than 10% organic revenue and over 15% earnings-per-share (EPS) growth. The company is leveraging increasing demand for veterinary diagnostics, innovation in diagnostic tools like inVue Dx FNA, and expansion into canine cancer testing as key drivers. IDEXX noted that while it expects a roughly 1.5% decline in veterinary visits during the second half of the year, rising utilization of blood work—currently included in only about one out of five visits—is helping offset this trend. CEO Mike Erickson emphasized the growing medicalization and aging of pets as factors boosting demand for more advanced care. The company is also rolling out Cancer Dx by year-end to cover three major canine cancers, which could further drive reference-laboratory growth. IDEXX sees a $45 billion global opportunity in diagnostics but believes it remains underpenetrated.
Tickers: $IDXX
Topics: growth outlook product innovation veterinary diagnostics